Company intelligence / Profile preview

a:head bio

Vienna, Vienna, Austria

Ownership: Private
Development stage: Other

Overview

a:head bio has developed an innovative preclinical drug discovery platform based on human cerebral organoids—miniature brain-like structures grown from patient-derived cells. This approach aims to overcome limitations of animal models in neurological disease research. The company uses deep AI analytics on these complex human tissue models to identify new therapeutic opportunities for central nervous system disorders. No clinical results have been published yet; the focus remains on advancing their pipeline toward first-in-human studies.

Therapeutic areas: Neurology
Modalities: Small moleculeBiologicGene therapyCell therapymRNA-based drugs
Industry: Biotech

Partnerships

3Brain AG – collaboration on high-density MEA systems for neural activity screening in brain organoids [March 2021]IMBA – license and collaboration agreements [October 2019]

Beyond the preview

Go deeper on a:head bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on a:head bio.

Explore the full profile